POST-TEST

Oncology Today with Dr Neil Love: Progress in Myelodysplastic Syndromes

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **The Phase III ASCERTAIN trial demonstrated which of the following results with regard to the pharmacokinetic/pharmacodynamic profile of the oral cedazuridine and decitabine fixed-dose combination, supporting the FDA approval of this regimen for patients with intermediate- or high-risk myelodysplastic syndromes (MDS)?**
   a. Decitabine exposure inferiority in terms of total 5-day dosing compared to intravenous (IV) decitabine
   b. Decitabine exposure equivalence in terms of total 5-day dosing compared to IV decitabine
   c. Decitabine exposure superiority in terms of total 5-day dosing compared to IV decitabine

2. **Which of the following receptor proteins is the target of the novel antibody magrolimab, being investigated for the treatment of MDS?**
   a. CD47
   b. PD-1
   c. TIM-3

3. **Which of the following agents is being compared to an erythropoiesis stimulating agent (ESA) in the Phase III COMMANDS study for patients with ESA-naïve very low-, low- or intermediate-risk MDS requiring red blood cell transfusions?**
   a. Luspatercept
   b. Magrolimab
   c. Eprenetapopt

4. **Which of the following drug types best describes the mechanism of action of the novel agent pevonedistat, being investigated for the treatment of high-risk MDS?**
   a. Immune checkpoint inhibitor
   b. Bcl-2 inhibitor
   c. NEDD8-activating enzyme inhibitor